Alto Neuroscience Publishes Prime-Praxol Study Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Alto Neuroscience highlighted the publication in Nature Medicine of Prime-Praxol, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study was conducted and independently funded by investigators at Lund University, Sweden. Adults with elevated baseline anhedonia symptoms with a diagnosis of major depressive disorder, dysthymia, or bipolar depression were randomized to flexible-dose pramipexole or placebo, added to ongoing treatment, for nine weeks, followed by a six-month open-label extension period. On the primary endpoint, pramipexole reduced anhedonia significantly more than placebo on the Snaith-Hamilton Pleasure Scale, with significant improvements on independent measures of anhedonia and apathy with improvements maintained through a six-month open-label treatment period.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANRO
Wall Street analysts forecast ANRO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.790
Low
25.00
Averages
35.67
High
50.00
Current: 21.790
Low
25.00
Averages
35.67
High
50.00
About ANRO
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alto Neuroscience CEO Amit Etkin Receives Transformational Research Award
- Leadership Recognition: Alto Neuroscience founder and CEO Amit Etkin, M.D., Ph.D., has been awarded the Transformational Research Award by the VP&S Alumni Association at Columbia University, highlighting his significant impact on the treatment of mental health disorders.
- R&D Innovation: Dr. Etkin's Precision Psychiatry Platform™ aims to personalize mental health treatment by analyzing EEG, neurocognitive assessments, and wearable data to identify patients most likely to respond to specific therapies, potentially reshaping the industry.
- Clinical Pipeline Development: Alto's clinical-stage pipeline includes programs for major depressive disorder, bipolar depression, treatment-resistant depression, and schizophrenia, with multiple mid- to late-stage data readouts expected over the next two years, which could significantly enhance the company's market position in biopharmaceuticals.
- Academic-Industry Synergy: Dr. Etkin's academic background at Columbia University and collaboration with Nobel laureate Dr. Kandel have enabled him to bridge elite academic research with industrial innovation, driving fundamental changes in mental health treatment and showcasing a successful partnership between academia and industry.
See More
Alto Neuroscience Reports Q1 2026 Financial Results
- Financial Performance: Alto Neuroscience reported a Q1 2026 GAAP EPS of -$0.80, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Cash Position: As of March 31, 2026, the company had approximately $264.2 million in cash, cash equivalents, and restricted cash, a significant increase from $177.0 million as of December 31, 2025, primarily due to net proceeds of about $115 million from the March 2026 PIPE, although cash was still used in operations during the quarter.
- Net Loss: The company incurred a net loss of $26.2 million for Q1 2026, compared to a net loss of $15.2 million for the same period in 2025, indicating a need for improved cost control and revenue generation efforts.
- Financing Update: Alto Neuroscience recently announced a $120 million private placement financing, aimed at strengthening its capital base to support future research and operational activities.
See More
Major Wall Street Rating Updates
- Chipotle Upgrade: Argus upgraded Chipotle Mexican Grill from Hold to Buy, indicating a return to growth, which reflects market optimism about the company's future performance.
- Full Truck Alliance Initiation: Bank of America initiated coverage on Full Truck Alliance (FTA) with a Buy rating and a price target of $11.3, implying a 33% total return potential, showcasing confidence in its business model.
- Alto Neuroscience Promising Outlook: Bank of America initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and a $35 price target, emphasizing its innovative potential in treating psychiatric disorders, which may attract more investor interest.
- Amazon Supply Chain Expansion: Bank of America reiterated its Buy rating on Amazon, highlighting the significant market potential of Amazon Supply Chain Services, which offers comprehensive logistics solutions for all businesses, further solidifying its market leadership.
See More
US Stocks Close Mixed Amid Oil Surge and Economic Data
- Market Fluctuations: The S&P 500 Index closed up 0.11%, while the Dow Jones Industrial Average fell 0.13%, and the Nasdaq 100 Index rose 0.11%, reflecting volatility influenced by surging oil prices and economic data.
- Positive Economic Data: Weekly initial unemployment claims unexpectedly fell by 9,000 to 202,000, indicating a stronger labor market than the anticipated increase to 212,000, which could impact the Fed's interest rate policy.
- Impact of Oil Surge: Crude oil prices soared over 11% due to President Trump's tougher stance on Iran, leading to sharp declines in airline and cruise line stocks, with United Airlines and Carnival both down more than 3%.
- Corporate Developments: SBA Communications surged over 18% as it explores potential acquisition options, while Globalstar rose over 13% amid reports of Amazon's interest in acquiring the company, highlighting market focus on M&A activity.
See More
Analysis of ALTO-101 Clinical Trial Failure Impact
- ALTO-101 Trial Failure: Alto Neuroscience's ALTO-101 failed to meet key goals in its Phase 2 study, resulting in a 7% drop in stock price on Thursday, indicating weakened market confidence in its schizophrenia treatment and potential impacts on future funding capabilities.
- Analyst Target Adjustments: Baird lowered Alto's price target from $41 to $38 while maintaining an 'Outperform' rating, emphasizing that the depression pipeline remains a key driver of the company's valuation, reflecting a reassessment of its potential value in the market.
- Cash Reserves Support: H.C. Wainwright highlighted Alto's strong cash position of $275 million, which supports its other R&D projects despite the failure of ALTO-101, maintaining a 'Buy' rating and a $50 price target, demonstrating confidence in the company's long-term prospects.
- Retail Sentiment Shift: Despite the stock's decline, retail investor sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating optimism about Alto's future potential, with the stock gaining over 20% year-to-date.
See More
Stock Markets Pressured by Soaring Oil Prices
- Oil Price Surge Pressures Markets: Stock indexes are under pressure as crude oil prices soar over 8% following President Trump's aggressive stance on Iran, leading to a 0.06% drop in the S&P 500, a 0.23% decline in the Dow, and a 0.20% fall in the Nasdaq 100, indicating heightened inflation concerns among investors.
- Unexpected Jobless Claims Drop: Despite market pressures, initial jobless claims fell by 9,000 to 202,000, indicating a stronger labor market than anticipated, which may provide some support for stocks and alleviate investor fears of an economic slowdown.
- Divergent Energy Sector Performance: Energy producers like Diamondback Energy rose over 2% due to soaring WTI prices, while airline stocks such as American Airlines and Carnival fell more than 4% as rising fuel costs cut into profits, highlighting a clear divergence across sectors.
- Tech Stocks Decline: Chipmakers and AI infrastructure stocks retreated, with ARM Holdings leading the Nasdaq 100 down over 5%, reflecting waning confidence in tech stocks and potentially impacting future investment decisions.
See More
Alto Neuroscience CEO Amit Etkin Receives Transformational Research Award
- Leadership Recognition: Alto Neuroscience founder and CEO Amit Etkin, M.D., Ph.D., has been awarded the Transformational Research Award by the VP&S Alumni Association at Columbia University, highlighting his significant impact on the treatment of mental health disorders.
- R&D Innovation: Dr. Etkin's Precision Psychiatry Platform™ aims to personalize mental health treatment by analyzing EEG, neurocognitive assessments, and wearable data to identify patients most likely to respond to specific therapies, potentially reshaping the industry.
- Clinical Pipeline Development: Alto's clinical-stage pipeline includes programs for major depressive disorder, bipolar depression, treatment-resistant depression, and schizophrenia, with multiple mid- to late-stage data readouts expected over the next two years, which could significantly enhance the company's market position in biopharmaceuticals.
- Academic-Industry Synergy: Dr. Etkin's academic background at Columbia University and collaboration with Nobel laureate Dr. Kandel have enabled him to bridge elite academic research with industrial innovation, driving fundamental changes in mental health treatment and showcasing a successful partnership between academia and industry.
See More
Alto Neuroscience Reports Q1 2026 Financial Results
- Financial Performance: Alto Neuroscience reported a Q1 2026 GAAP EPS of -$0.80, indicating ongoing challenges in profitability and reflecting persistent financial pressure on the company.
- Cash Position: As of March 31, 2026, the company had approximately $264.2 million in cash, cash equivalents, and restricted cash, a significant increase from $177.0 million as of December 31, 2025, primarily due to net proceeds of about $115 million from the March 2026 PIPE, although cash was still used in operations during the quarter.
- Net Loss: The company incurred a net loss of $26.2 million for Q1 2026, compared to a net loss of $15.2 million for the same period in 2025, indicating a need for improved cost control and revenue generation efforts.
- Financing Update: Alto Neuroscience recently announced a $120 million private placement financing, aimed at strengthening its capital base to support future research and operational activities.
See More
Major Wall Street Rating Updates
- Chipotle Upgrade: Argus upgraded Chipotle Mexican Grill from Hold to Buy, indicating a return to growth, which reflects market optimism about the company's future performance.
- Full Truck Alliance Initiation: Bank of America initiated coverage on Full Truck Alliance (FTA) with a Buy rating and a price target of $11.3, implying a 33% total return potential, showcasing confidence in its business model.
- Alto Neuroscience Promising Outlook: Bank of America initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and a $35 price target, emphasizing its innovative potential in treating psychiatric disorders, which may attract more investor interest.
- Amazon Supply Chain Expansion: Bank of America reiterated its Buy rating on Amazon, highlighting the significant market potential of Amazon Supply Chain Services, which offers comprehensive logistics solutions for all businesses, further solidifying its market leadership.
See More
US Stocks Close Mixed Amid Oil Surge and Economic Data
- Market Fluctuations: The S&P 500 Index closed up 0.11%, while the Dow Jones Industrial Average fell 0.13%, and the Nasdaq 100 Index rose 0.11%, reflecting volatility influenced by surging oil prices and economic data.
- Positive Economic Data: Weekly initial unemployment claims unexpectedly fell by 9,000 to 202,000, indicating a stronger labor market than the anticipated increase to 212,000, which could impact the Fed's interest rate policy.
- Impact of Oil Surge: Crude oil prices soared over 11% due to President Trump's tougher stance on Iran, leading to sharp declines in airline and cruise line stocks, with United Airlines and Carnival both down more than 3%.
- Corporate Developments: SBA Communications surged over 18% as it explores potential acquisition options, while Globalstar rose over 13% amid reports of Amazon's interest in acquiring the company, highlighting market focus on M&A activity.
See More
Analysis of ALTO-101 Clinical Trial Failure Impact
- ALTO-101 Trial Failure: Alto Neuroscience's ALTO-101 failed to meet key goals in its Phase 2 study, resulting in a 7% drop in stock price on Thursday, indicating weakened market confidence in its schizophrenia treatment and potential impacts on future funding capabilities.
- Analyst Target Adjustments: Baird lowered Alto's price target from $41 to $38 while maintaining an 'Outperform' rating, emphasizing that the depression pipeline remains a key driver of the company's valuation, reflecting a reassessment of its potential value in the market.
- Cash Reserves Support: H.C. Wainwright highlighted Alto's strong cash position of $275 million, which supports its other R&D projects despite the failure of ALTO-101, maintaining a 'Buy' rating and a $50 price target, demonstrating confidence in the company's long-term prospects.
- Retail Sentiment Shift: Despite the stock's decline, retail investor sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating optimism about Alto's future potential, with the stock gaining over 20% year-to-date.
See More
Stock Markets Pressured by Soaring Oil Prices
- Oil Price Surge Pressures Markets: Stock indexes are under pressure as crude oil prices soar over 8% following President Trump's aggressive stance on Iran, leading to a 0.06% drop in the S&P 500, a 0.23% decline in the Dow, and a 0.20% fall in the Nasdaq 100, indicating heightened inflation concerns among investors.
- Unexpected Jobless Claims Drop: Despite market pressures, initial jobless claims fell by 9,000 to 202,000, indicating a stronger labor market than anticipated, which may provide some support for stocks and alleviate investor fears of an economic slowdown.
- Divergent Energy Sector Performance: Energy producers like Diamondback Energy rose over 2% due to soaring WTI prices, while airline stocks such as American Airlines and Carnival fell more than 4% as rising fuel costs cut into profits, highlighting a clear divergence across sectors.
- Tech Stocks Decline: Chipmakers and AI infrastructure stocks retreated, with ARM Holdings leading the Nasdaq 100 down over 5%, reflecting waning confidence in tech stocks and potentially impacting future investment decisions.
See More
